Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Radiation Oncology, BC Cancer - Vancouver, Vancouver, British Columbia, Canada.
JCO Oncol Pract. 2021 Feb;17(2):e178-e185. doi: 10.1200/JOP.19.00808. Epub 2020 Jun 25.
There is limited evidence to support the routine use of conformal radiotherapy (RT) techniques in the treatment of bone metastases. This study evaluated trends in advanced technique use within the province of British Columbia.
Data on patients who received RT for bone metastases between 2009 and 2016 (with the exception of 2012) at 6 regional cancer centers were reviewed. Descriptive statistics summarized radiation technique patterns. Logistic regression assessed the influence of patient, treatment, and provider variables on receipt of RT technique.
A total of 24,215 RT courses were identified; 97% were planned by simple RT and 3% by advanced techniques (3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and stereotactic body radiotherapy). The use of advanced techniques was significantly higher in recent years compared with in 2009 (odds ratios [ORs], 2.2, 4.2, 4.2, and 6.3, respectively, for the years 2013 to 2016; < .001). Patients with thyroid, sarcoma, and neuroendocrine malignancies (ORs, 10.3, 5.5, and 5.2, respectively; < .005) were more likely to be treated with advanced techniques, as were skull, sternum, rib, and pelvic metastases (ORs, 8.0, 5.2, 2.2, and 2.2, respectively; < .001). Advanced techniques were most commonly used in the setting of re-irradiation (38%). They were associated with slightly higher incompletion rates (3.0% 1.5%, < .005) and less use within 30 days of death (6% 15%, < .001).
Within our publicly funded, salary-based provincial health care system, we found that the majority of bone metastases are still being treated by simple RT; however, the use of advanced techniques is increasing, and we identified select patterns in which they are being prescribed. Additional study into clinical benefit is required.
有有限的证据支持常规使用适形放疗(RT)技术治疗骨转移。本研究评估了不列颠哥伦比亚省先进技术使用的趋势。
对 2009 年至 2016 年(2012 年除外)期间在 6 个区域癌症中心接受 RT 治疗的骨转移患者的数据进行了回顾。描述性统计总结了放射技术模式。逻辑回归评估了患者、治疗和提供者变量对接受 RT 技术的影响。
共确定了 24215 例 RT 课程;97%是通过简单 RT 计划的,3%是通过先进技术(三维适形放疗、调强放疗和立体定向体放疗)计划的。与 2009 年相比,近年来先进技术的应用显著增加(2013 年至 2016 年的优势比分别为 2.2、4.2、4.2 和 6.3;<0.001)。患有甲状腺、肉瘤和神经内分泌恶性肿瘤的患者(优势比分别为 10.3、5.5 和 5.2;<0.005)更有可能接受先进技术治疗,颅骨、胸骨、肋骨和骨盆转移(优势比分别为 8.0、5.2、2.2 和 2.2;<0.001)。先进技术最常用于再放疗(38%)。它们与略高的未完成率(3.0% 1.5%;<0.005)和在死亡后 30 天内使用率较低(6% 15%;<0.001)相关。
在我们的公共资助、基于工资的省级医疗保健系统中,我们发现大多数骨转移仍通过简单 RT 治疗;然而,先进技术的使用正在增加,我们确定了一些规定它们的模式。需要进一步研究临床获益。